Company: TELO
Filing Date: 2025-11-10
Form Type: 10-Q
Source: 0001493152-25-021496
Chunk: 16

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-11-10
Form: 10-Q
Item: Item 1
Chunk 16
---
 was granted 2,000,000 options to purchase Common Stock with an aggregate fair market value of approximately
$3.7 million. The options have a term of 10 years from the grant date and were all vested as of the grant date.

The
fair value of the options granted in 2025 were estimated on the grant date using the Black-Sholes valuation method and level 3 inputs
based on assumptions for expected volatility, expected dividends, expected term and the risk-free interest rate which resulted in $3.8
million in option valuation during the nine months ended September 30, 2025.

Key
assumptions used to value warrants issued in the quarter are as follows:

Schedule
of key assumptions used to value warrants issued 

    Expected price volatility range 
     92.45%-138.97% 

    Risk-free interest rate range 
     4.08%-4.15% 

    Fair Market Value of Underlying Common Stock range 
     $1.87-$2.06 

    Expected Term in Years range 
     5-5.37 years 

    Dividend yield 
     - 

Unrecognized
compensation expenses as of September 30, 2025 was $0.13 million to be recognized through September 2026. The Company recognized approximately
$5.3 million in stock-based compensation in the nine months ended September 30, 2025.

    12

Note
6. Segment Information

The
Company operates in one reportable segment related to the development and commercialization of pharmaceuticals targeting neurologic and
neuropsychiatric disorders. The CODM for the Company is the Chief Executive Officer (the “CEO”). The Company’s CEO
reviews operating results on an aggregate basis and manages the Company’s operations as a whole for the purpose of evaluating financial
performance and allocating resources. Accordingly, the Company has determined that it has a single reportable and operating segment structure.
The CEO uses aggregate net loss to allocate resources in the annual budgeting and forecasting process and also uses that measure as a
basis for evaluating financial performance regularly by comparing actual results with established budgets and forecasts.

The
accounting policies of the Company’s single segment are the same as those described in the summary of significant accounting policies
within Note 1. The CEO assesses performance for the Company and decides how to allocate resources based on the aggregate net loss that
is also reported on the statement of operations as net loss. The